Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Acquisitions & Divestments (2017 - 2025)

VYNE Therapeutics' Change in Acquisitions & Divestments history spans 7 years, with the latest figure at $14.2 million for Q2 2025.

  • For Q2 2025, Change in Acquisitions & Divestments fell 44.98% year-over-year to $14.2 million; the TTM value through Jun 2025 reached $94.4 million, up 151.6%, while the annual FY2025 figure was $68.3 million, 18.69% down from the prior year.
  • Change in Acquisitions & Divestments reached $14.2 million in Q2 2025 per VYNE's latest filing, down from $33.6 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $33.6 million in Q1 2025 to a low of $1.0 million in Q2 2021.
  • Average Change in Acquisitions & Divestments over 3 years is $19.0 million, with a median of $22.9 million recorded in 2024.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 95.15% in 2021, then soared 189.66% in 2025.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $1.0 million in 2021, then soared by 2129.8% to $22.9 million in 2024, then tumbled by 37.77% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Change in Acquisitions & Divestments are $14.2 million (Q2 2025), $33.6 million (Q1 2025), and $22.9 million (Q4 2024).